Bringing patients into focus
with ocular gene therapy
Atsena Therapeutics is conducting clinical trials for inherited retinal diseases with our investigational gene therapies.
Atsena is evaluating ATSN-101 in an ongoing Phase I/II clinical trial (clinicaltrials.gov identifier: NCT03920007) in patients with GUCY2D-associated Leber congenital amaurosis (LCA1). Learn more about the clinical trial here: https://clinicaltrials.gov/ct2/show/NCT03920007
This study is active, but no longer recruiting.
Atsena is leveraging one of its novel spreading capsids, AAV.SPR, in a Phase I/II clinical trial (ClinicalTrials.gov Identifier: NCT05878860) to evaluate ATSN-201 for X-linked retinoschisis (XLRS). Learn more about the clinical trial here: https://www.clinicaltrials.gov/ct2/show/NCT05878860
This study is active and recruiting.
Contact us with questions at email@example.com
All of Atsena’s gene therapy products are investigational. Safety and efficacy have not been established by the FDA or other regulatory bodies. To view our policy on compassionate use and expanded access, click here.